Wedbush Securities’s Actinium Pharmaceuticals ATNM Stock Holding History

Wedbush Securities’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-333	Closed	-$2K	–	891
2019 Q4	$2K	Hold	333	–	–	﹤0.01%	992
2019 Q3	$2K	Hold	333	–	–	﹤0.01%	976
2019 Q2	$2K	Hold	333	–	–	﹤0.01%	984
2019 Q1	$5K	Hold	333	–	–	﹤0.01%	922
2018 Q4	$4K	Hold	333	–	–	﹤0.01%	832
2018 Q3	$7K	Hold	333	–	–	﹤0.01%	895
2018 Q2	$6K	Buy	+333	New	+$4.22K	﹤0.01%	877

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wedbush Securities's ATNM Position: Q1 2020 in Review

Wedbush Securities sold out of Actinium Pharmaceuticals (ATNM) in Q1 2020, closing a stake of 333 shares — an estimated $2K sold.

Wedbush Securities first reported a position in ATNM in Q2 2018 and held it in 7 quarters. The position peaked at $7K in Q3 2018. 42 funds tracked by Wall St. Rank hold ATNM as of Q1 2020.

Wedbush Securities reported no remaining Actinium Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Wedbush Securities sold 333 Actinium Pharmaceuticals shares in Q1 2020, an estimated $2K.
Wedbush Securities first reported a position in Actinium Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Wedbush Securities's Actinium Pharmaceuticals position peaked at $7K in Q3 2018.
42 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2020.

Based on Wedbush Securities's 13F filing for Q1 2020, filed 17 Apr 2020.